The 2016 World Health Organization (WHO) classification for myeloproliferative neoplasms (MPN) divided myelofibrosis (MF) into pre-fibrotic (pre-MF) and overt-MF categories. This new classification, particularly the entity pre-MF, has been a subject of discussion between experts. Important questions have been raised in recent years, such as the need for bone marrow trephine for diagnosis; how this is interpreted and the weighting given to it in assigning a diagnosis; determination of prognosis for pre-MF patients; including which scoring system to use and, ultimately, an evidencebased management plan for this group of patients. Many pre-MF patients present as young adults, with thrombocytosis, elevated lactate dehydrogenase levels and increased bone marrow fibrosis (i.e. ≥ grade 1). Current management strategies differ in view of age, comorbidities and bone marrow features and the opinion of the managing clinicians. Prognostic scoring systems have some limitations regarding this entity, and at the present time there is limited information about the overall survival and incidence of progression to overt-MF and acute leukaemia for pre-MF. In this clinically focussed article, we review the main characteristics of this new disease category in view of the current published literature and illustrate our discussion with some real patient cases. Lastly, we propose a management strategy for patients to whom this diagnostic label is applied.
Historical perspective
Before 2016, three classical myeloproliferative neoplasms (MPNs) were included in the WHO classification. All were diagnosed by standardized criteria following the WHO 2008 classification (Swerdlow et al, 2008) and subsequently managed according to adapted scoring systems, based on age and history of thrombosis (for ET or PV patients) or the International Prognosis Scoring System (IPSS) and dynamic IPSS (DIPSS) (for patients with MF) (Barbui et al, 2011a) .
The first description of the entity pre-MF was published almost 20 years ago (Thiele et al, 1999) , but this was not incorporated in the 2001 WHO myeloid classification that almost immediately followed this paper. Initially, pre-MF was integrated within primary MF in the 2008 WHO classification (Swerdlow et al, 2008) . It is important to note that the diagnostic criteria for pre-MF have altered over time, although the fundamental histopathological features have not, and the minor criteria have been amended. As a consequence of amendments in diagnostic criteria, the various groups of patients reported in the historical literature as pre-MF might differ from those whom would be described by the current WHO classification (Arber et al, 2016) .
At the present time, the prevalence of pre-MF is not known. However, considering a report of patients diagnosed with ET (Barbui et al, 2011b) , 180/1071 patients (16Á8%) could be called pre-MF according to the pathologists' perspective. On the other hand, the number of pre-MF cases among patients previously classed as primary-MF has been reported to be as high as 42% (278/661) (Guglielmelli et al, 2017;  Table II) .
Making a diagnosis of pre-MF
In 2016, pre-MF was introduced as a separate entity with specific characteristics comprising histopathological and clinical/biological parameters (Arber et al, 2016) , as shown in Table I . The minor criteria for this entity are different from overt-MF as presence of leucoerythroblastosis is not an option and the histopathological features have particular prominence in discriminating pre-MF from ET or PV, for example. Concerning diagnostic reliability, as in other disorders this may be problematic. Intra and inter-professional reproducibility is imperfect (i.e. between 53% and 88%) (Wilkins et al, 2008; Guglielmelli et al, 2017) and is a challenge that both histopathologists and haematologists need to be aware of. It is essential to consider the quality and quantity of the bone marrow samples, adequate investigations and medical history within a multi-disciplinary process for these cases. In some situations, our preference would be to use the label MPN-unclassified and to revisit the diagnosis periodically. The current diagnostic criteria are listed in Table I . The final diagnosis of pre-MF should be posed if the patient had three major criteria and at least one minor criterion. Patients who lack so-called classical driver mutations in the JAK2, CALR or MPL genes and have so-called "triplenegative" (TN) disease should be very carefully evaluated. Investigations for other so-called non-driver mutations, such as TET2, IDH1/IDH2, SRSF2 and SF3B1, could be useful to delineate the clonal status of the disease, but variant allele frequency and the possibility of clonal haematopoiesis of indeterminate potential (CHIP) would need to be considered (Jaiswal et al, 2017) .
Challenges in the clinical management of pre-MF Several patient cohorts have been published comparing the characteristics and the outcomes of patients with a diagnosis of pre-MF to those with either ET or of overt-MF. These comparative studies are shown in Table II and discussed in detail below. Importantly, some significant differences in patient outcomes are highlighted and have been used to justify the existence of this new entity within the WHO classification. At the present time, there is no specific management algorithm for patients with pre-MF. Due to the "MF" part of their condition, some patients are managed like overt-MF Table I . Prefibrotic and overt myelofibrosis diagnosis according to current WHO classification. Compiled from Arber et al (2016) .
Pre-MF
Overt-MF
Major criteria
• Bone marrow examination: hyper-and dysmegakaryocytopoiesis without a significant fibrosis (WHO grade 0-1), granulocytic proliferation and often decreased erythrocytosis.
• Bone marrow exam: megakaryocytic proliferation and atypia with reticulin fibrosis (WHO fibrotic grade 2-3).
• Molecular analysis: identification of a clonal marker (e.g. JAK2 V617F)
• Absence of another myeloid disorder n a n a n a n a n a n a Thromboses before diagnosis (%) (Barosi et al, 2012; Guglielmelli et al, 2017; Mudireddy et al, 2017) . Some patients however do not have the profile of overt-MF and may instead mimic ET or PV, and indeed have a similar outcome to these conditions. The overlapping disease spectrum and the lack of detailed information regarding risk assessment and for evidence-based treatment complicates the management of these patients with pre-MF. For instance: which profile of the patients should be used for setting a management plan (ET or PV versus pre-MF, overt-MF versus pre-MF)? Should we treat the patient to prevent thrombosis? Should we focus on constitutional symptoms or spleen size? Should we counsel the patient that they may need a stem cell transplant in the coming decade less or more? We will discuss comparative studies and prognostic scores below, and finally illustrate this with clinical cases.
Considering pre-MF versus ET
In terms of clinical characteristics, as discussed by Barbui et al (2011b) , it seems that there may sometimes only be a few subtle differences between ET and pre-MF patients (Table II) . The median age at diagnosis was similar and corresponded with the low-risk group (56 and 57 years, respectively), and both populations were clearly more often female (58Á8% and 58Á5%, respectively), a classical feature of this population. Whilst the rate of palpable splenomegaly seemed significantly higher in pre-MF cases (23% vs. 16%) this could not be used to discriminate the two. In terms of full blood counts, patients with pre-MF are more proliferative considering leucocytes and platelets but have a lower haemoglobin. Furthermore, both the lactate dehydrogenase (LDH) level and CD34+ cell count were higher in pre-MF. Concerning driver mutations, recent publications reported the following for ET and pre-MF respectively: JAK2 V617F 66Á5% vs. 52Á3%; CALR 17Á8% vs. 35Á8%, MPL 3Á4% vs. 6Á4% TN 12Á3% vs. 5Á5% and JAK2 V617F 63% vs. 40%, CALR 24% vs. 35%, MPL 2% vs. 0% and TN 12% vs. 25% (Palandri et al, 2015 ) (see Table II ). The importance of differentiating ET from pre-MF would be enhanced if different management strategies were employed. Efforts to more reliably differentiate the entities has been addressed with workshop-based education and in a more formal way by two groups who used a modelling technique utilising the differences described above Schalling et al, 2017) . Nevertheless, even using these sophisticated techniques, clinical and laboratory features were, at best, only able to differentiate 40-50% of patients. The model proposed by Schalling et al (2017) relied on the use of a specific formula: here the pre-MF probability was predicted by a regression modelling that can be used as a prediction score ranging from 0 (ET) to 1 (pre-MF); calculated using the following formula: Table II DIPSS, dynamic International Prognostic Scoring System; LDH, lactate dehydrogenase; na, not available; PB, peripheral blood; Pre-MF, prefibrotic myelofibrosis; WBC, white blood cell count. *Unfavourable karyotype, defined as complex karyotype (3) chromosomal abnormalities, or 1-2 abnormalities that include
In this formula, log 2 denotes the binary logarithm and 1 is inserted for splenomegaly, if the spleen is palpable or ≥12 cm in length (diameter) in any imaging and zero otherwise. To transform this score into a dichotomous classification rule (ET versus pre-MF) a cut-off equal to 0Á438 is proposed, which leads to approximately equal sensitivity and specificity. Importantly both authors emphasized the critical importance of not over treating patients by incorrectly assuming a diagnosis of pre-MF when those patients would be more correctly diagnosed as ET Schalling et al, 2017) .
Whether a formula such as that above is used in the future to enhance diagnostic reliability or not, ultimately, diagnosis could also be improved by improving expertise in interpreting bone marrow biopsies or identifying a novel biological feature.
Regarding clinical complications, patients with pre-MF compared with ET have higher risks of bleeding and transformation into overt-MF or acute myeloid leukaemia (AML), inducing an overall shorter median survival compared to patients with ET (Barbui et al, 2011b) . No difference was observed for thrombosis, which was 18Á5% and 18% at 10 years (P > 0Á90) in this series or others . However, interestingly and very importantly, in at least one series these differences completely disappeared if only patients below 40 years old were considered (Palandri et al, 2015) ; the reason for this is unclear and may be a function of the duration of follow-up but should be evaluated further.
Considering pre-MF versus overt-MF
Considering the data presented in Table II , in terms of clinical characteristics, both youth and female gender seem to be more represented in pre-MF compared to overt-MF groups (Guglielmelli et al, 2017; Mudireddy et al, 2017) . Symptoms and palpable splenomegaly are less common in the pre-MF group. In contrast, patients with pre-MF seemed to have more pronounced leucocytosis and thrombocytosis and have less anaemia with lower LDH levels than patients with overt-MF. The proportions of driver mutations seem to greatly vary in the published cohorts, for example in Guglielmelli et al (2017) found that JAK2 V617F positive cases were 67Á2/58Á2% and TN cases were 10Á1/13Á6%, (pre-MF/overt-MF); whereas they were 59/66% and 22/9% in the analysis by Mudireddy et al (2017) . On the other hand, high molecular risk mutations (defined as presence of ASXL1, EZH1, IDH1/2 and SRSF2) and abnormal karyotypes (+8, -7/7q-, i(17q), inv(3), -5/5q-, 12p-or 11q23 rearrangement, are less frequent among pre-MF cases (Barosi et al, 2012; Guglielmelli et al, 2017) .
In terms of complications, the rate of AML was lower among pre-MF patients compared with overt-MF (8Á3% vs. 12Á8%) and the median overall survival was significantly higher, in fact double when compared to overt-MF patients (14Á7 years vs. 7Á2 years) ( Table II) . The latter is probably because according to the IPSS and DIPSS scores, patients with pre-MF were more often classified as low and intermediate-1 risk compared with those patients whose diagnosis was overt-MF. Importantly however, as discussed below, the outcome of pre-MF patients when divided into IPSS intermediate 1 and 2 groups are not different (Guglielmelli et al, 2017) , thus we could not suggest using these prognostic scores without being aware of this problem. Few studies have reported rates for major thrombotic events in these populations and, interestingly, it appears to be moderately higher in pre-MF compared to overt-MF (Barosi et al, 2012) .
Considering pre-MF versus PV
There is limited literature when considering pre-MF versus PV, however, there are some reports that pre-MF patients may have high haematocrit and haemoglobin (Barosi et al, 2012) and, under these circumstances, could mimic a patient with PV. Interestingly, in our experience some patients with a haemoglobin or haematocrit in the upper range of normal may have pathology reported as possibly consistent with pre-MF: Patient 4 (described below) illustrates this, although this patient's haemoglobin was clearly in the polycythaemic range. An adequate bone marrow trephine reported by an experienced haematopathologist is crucial, together with investigations to exclude the presence of an erythrocytosis, such as a red cell mass if available, is required in this setting, especially in a patient with a JAK2 V617F mutation. Furthermore, it is notable, as highlighted by Gisslinger (2017) , that survival for patients with pre-MF is very similar to that for patients with PV.
How to gauge prognosis in pre-MF As we consider the implications of distinguishing pre-MF as an entity separated from overt-MF or, indeed, other MPN, one of the most relevant issues for the haematologist is how to gauge prognosis and then select management of this group of patients appropriately. The main parameters of the prognostic scoring systems discussed below are summarised in Table III . The current prognostic scoring systems for overt-MF are IPSS, DIPSS (based upon age, leucocytes, anaemia, blasts and symptoms) and DIPSS-plus, which includes other values, such as transfusion, thrombocytopenia and unfavourable karyotype, as part of the scoring) (as summarised in Reilly et al, 2012; Gangat et al, 2011) . More recently, the Mutation-Enhanced International Prognostic Scoring System (MIPSS70) and MIPSS70-plus have also been published (Guglielmelli et al, 2018) . These may be more helpful than the IPSS and DIPSS scores given that, in the seminal work of Guglielmelli et al (2018) , as highlighted above, it is apparent that conventional prognostic scores such as the IPSS cannot On the other hand, for ET patients the International Prognostic Score for Essential Thrombocytopenia (IPSET) scoring system classifies ET patients according to thrombosis risk and separately for prognostic group . Although its usage has been controversial due to lack of prospective validation, it was included in the most recent European leukaemia net (ELN) MPN management guidelines and in the National Comprehensive Cancer Network (NCCN) guidelines (Mesa et al, 2017) . In clinical practice, patients are often more traditionally stratified based upon age, prior thrombosis and cardiovascular risk factors, as also discussed by the ELN and NCCN. Either approach may be suitable for pre-MF patients but should ideally be validated. Perhaps in the future, the impact of both driver mutations and those in other non-driver genes in addition to cytogenetics will prove more critical for both for thrombosis and survival. Barosi et al (2012) showed a higher incidence of splenic thrombosis in pre-MF patients, suggesting that this could be associated with the high prevalence of JAK2 V617F in this group (Barosi et al, 2012) . The subtype of CALR mutation, i.e. type 1 or type 2, has a diverse impact on survival in ET and overt-MF patients, with type 1 having a positive impact in overt-MF patients . However, this has not been well defined in pre-MF and would be an interesting area to explore. The MIPSS score includes the presence of non-driver mutations (e.g. ASXL1, TET2, EZH2, SRSF2, DNMT3A, U2AF1 and IDH1/IDH2) and was developed mainly to select patients for high risk therapeutic strategies, such as allogeneic stem cell transplant procedures (Guglielmelli et al, 2018) . Such analyses may be more helpful for pre-MF patients and could be a useful contribution to the field, but this is unclear at the present time.
At present, as we have discussed, most patients with pre-MF lie within the lower prognostic IPSS or DIPSS groups and have a long-projected overall survival, thus the risk of thrombotic complications is cumulatively an issue. In keeping with this, the most common clinical presentation for these patients is thrombocytosis and leucocytosis and several studies have shown a higher incidence of thrombosis in pre-MF when compared with overt-MF, and even ET (detailed in Table II) . Therefore, it is likely that a thrombosis-based risk approach should be considered more appropriate for the pre-MF group to define an adequate immediate management. Future prognostic scores should be developed to more adequately predict AML MF transformation and prognosis given that several studies have demonstrated that overall survival in pre-MF patients is lower when compared with the ET population (Table II) . Under these circumstances, the risk of development of AML, either intrinsic to the disease or due to treatment for it, also becomes relevant. Actually, the data regarding the 10-year cumulative incidence of AML for pre-MF is highly variable, ranging from 2Á3% up to 36Á9% in other studies (Thiele et al, 2011; . Some of this variation may be due to older, but some may be due to the varying definitions of what constituted pre-MF, as discussed earlier. However, this data should be interpreted with caution until more information is available that will hopefully enable us to better determine the risk of progression in these patients in the future: this should be an urgent focus of clinical studies.
Management of pre-MF in 2018
Currently, there are no clear published guidelines to manage pre-MF patients and, as highlighted, this is not addressed in either the NCCN or the ELN guidelines (Mesa et al, 2017; Barbui et al, 2018) , both of which have been published since the 2016 WHO revision (Arber et al, 2016) . A key controversy is how to rationalise treatment of these patients and on what to base these decisions. For example, in view of the fibrosis and adverse outcome, should they be managed as overt-MF, applying the current IPSS or DIPSS scoring systems; or should treatment be based more upon the clinical profile when the focus might be to manage the thrombocytosis or erythrocytosis as in ET or PV respectively. Consensus on how to manage these patients has not yet been reached and, indeed, frequently constitutes our main problem in daily practice.
We present below four real cases of patients with a diagnosis of pre-MF recorded at some point during their clinical journey who were managed in different ways. The way that we treat patients is sometimes directly linked to the scoring prognosis and prognosis, but may also be problem-based (as per the recent ELN guidelines). Personal medical history, including comorbidities, clinical presentation (constitutional symptoms, thrombosis events or splenomegaly, for example), age and blood counts (e.g. extreme thrombocytosis and leucocytosis) should be integrated to make the treatment decision. The prevention of thrombosis remains the main indication for starting cytoreductive therapy in ET and PV patients, therefore it is important to consider this in pre-MF patients and evaluate other possible risk factors, e.g. cardiovascular risk factors. Molecular factors (e.g. JAK2 V617F mutations) should be added to the discussion in order to start cytoreductive therapy or not as it is known that, for instance, JAK2 V617F is associated with a higher risk of thrombosis and CALR mutations are associated with better thrombosis-free survival in ET. Importantly, when considering choice of therapy, the longer likely disease course and great risk of transformation to AML and overt-MF may have a bearing in choice of and timing of initiation of therapy although currently no data exists upon which to practice evidence-based medicine in this area, i.e. no treatments have been shown to reduce the risk of transformation to over-MF or AML. Figure 1 summarises our management proposal for these cases.
Description of four problematic cases
Cases from our practice have been chosen to illustrate the challenges inherent in managing patients who, at some point, were considered to meet current criteria for pre-MF (Table IV) . All these cases were initially identified as pre-MF by our histopathologists, but management and ultimate diagnosis was subsequently decided according to the clinicalbiological profile and assigned at a case discussion (i.e. ET, overt-MF or PV). This reflects the difficulties that histopathologists and haematologists may regularly confront with cases where there is less correlation between the findings on the bone marrow trephine and the clinical presentation of the patients. We strongly support the need for consensus 
Patient 1
A young woman presented at 26 years of age with thrombocytosis (platelet count >1500 9 10 9 /l, leucocyte count 8 9 10 9 /l and haemoglobin 122 g/l). She was also known to have factor XI deficiency and had no cardiovascular risk factors. A bone marrow trephine done in 1997 showed features consistent with pre-MF (although at that time the entity did not exist, and she was labelled as having ET) and her LDH was 860 iu/l [normal range: 135-225 iu/l]. No leucoerythroblastic features were present in the blood film and there was no splenomegaly. Initially the platelet count settled below 1500 9 10 9 /l and she was managed with a watch-and-wait strategy without aspirin due to the underlying haemophilia. Later, the patient required surgery and she commenced cytoreductive therapy (initially hydroxycarbamide and then anagrelide) to improve the platelet count prior to surgery. The patient had a miscarriage in 2000 and an uncomplicated pregnancy in 2012. A CALR (type 2) mutation was identified in 2015 and an ASXL1 mutation detected in 2017, 20 years after the original diagnosis when the haemoglobin first fell below the normal range and occasional left shift was detected in the blood film. This patient was initially classified as low risk ET according to the British Committee for Standards in Haematology guidelines (Harrison et al, 2010) ; currently the diagnosis has been adjusted to overt-MF, and the original diagnosis to pre-MF. Of note, there is neither a term for overt-MF arising from pre-MF, nor are there criteria to judge when this transformation occurs. There is no current evidence to suggest that early treatment of pre-MF delays progression to overt-MF and the patient remains on a watch-andwait strategy.
Patient 2
A male patient presented at 43 years of age with moderate thrombocytosis (platelets >600 9 10 9 /l, leucocytes 11Á2 9 10 9 /l, and a mild anaemia [haemoglobin 120 g/l] 
Patient 3
A 62-year-old male patient presented with a high platelet count 1330 9 10 9 /l, leucocytes 10Á6 9 10 9 /l, haemoglobin 140 g/l and splenomegaly 16 cm (on scan) and he was found to be JAK2 V617F-positive. A bone marrow biopsy showed WHO grade 1 fibrosis (interestingly there were focal areas of grade 2), but no leucoerythroblastic blood film features, the LDH was 376 [normal range, 135-225 iu/l] and there were no constitutional symptoms. A diagnosis of pre-MF was made, the IPSS score was low risk and DIPSS score was 0 but cytoreductive therapy was discussed due to the patient's age and the presence of thrombocytosis with the JAK2 V617F mutation. The patient was treated with low-dose aspirin and Pegylated-interferon alpha 1a.
Patient 4
A 40-year-old man, referred for erythrocytosis (haemoglobin 228 g/l, PCV 0Á65), had a pan-myelosis: platelet count was 607 9 10 9 /l and leucocyte count was 25 9 10 9 /l. The patient had dizziness and fatigue but no constitutional symptoms that were of prognostic relevance. Noted to be JAK2 V617F-positive, he was treated with venesection, after which the platelet count progressed to 1200 9 10 9 /l. A bone marrow was performed which showed features that were initially reported as compatible with pre-MF with fibrosis WHO grade 0. LDH was 399 (normal range, 135-225 iu/l) and no leucoerythroblastic features were noted, the spleen was at the upper limit of normal. The patient had co-existing hypertension and was also treated for hypercholesterolaemia. Following clinic-pathological discussion this patient was diagnosed with PV and received low-dose aspirin and Pegylated-interferon alpha 1a.
It is apparent that these cases, in which the initial bone marrow was (or would have been, for Patient 1) reported as pre-MF, all have overlapping features regarding clinical presentation, with thrombocytosis in all cases and 3 of them having splenomegaly. However, the final diagnosis was different and consequently, the management approach was based upon the final diagnosis and in view of risk factors, such age and comorbidities. For example, Patients 1 and 2 had a similar profile and the initial histopathological diagnosis would have been similar. The patients have the same management strategy, watch-and-wait, but the ultimate diagnosis and prognosis are different.
A number of further points are illustrated by these cases. First, in our institution the final diagnosis and management of individual cases is reached based upon an integration of available data by the clinician who assessed the patient and, for these cases, this differed on the basis of the clinical profile rather than the pathological diagnosis. A particular illustration of this is Patient 4, where the diagnosis was clearly PV and a diagnostic bone marrow biopsy may not even have been required. The next consideration is optimization of vascular risk factors because the most common complication remains vascular events. The remaining question is with regard to treatment, i.e., whether to introduce cytoreductive treatment or not, as this will all depend upon the individual case. For example, Patient 1 started treatment because of surgery and then stopped it in the post-operative period; Patients 3 and 4 started interferon due to age and vascular risk.
Conclusion
The inclusion within the 2016 WHO classification of the entity, pre-MF, characterized by low grade bone marrow fibrosis, particular features of megakaryocytes, and variably elevated LDH, leucocytosis, splenomegaly, mild anaemia and thrombocytosis (Arber et al, 2016 ) poses difficult problems in clinical practice. These problems arise from significant overlapping features with the classical MPN making the diagnosis sometimes challenging. Nonetheless, if pre-MF can indeed be identified reliably and has a different prognosis, then this decision to identify a new entity is welcome. Subsequently, this poses a challenge in day-to-day clinical practice, as we have highlighted. For example, it remains unclear which prognostic scoring system should be used for these patients and when different treatments would be indicated. Therefore, in current clinical practice, the answer to the question of which approach should be used in the management of pre-MF is not evidence-based and it is likely an individual patient approach should best be considered in the context of a multidisciplinary discussion. In the future, data from well-annotated patient registries will help us to better understand the clinical presentation of this condition and the best approach the management of patients, including risk assessment. Major advances in the field occurred with scientific discoveries, such as the JAK2 V617F mutation; similarly, large scale biological studies linked to patient outcome data are likely to provide some of the answers we seek with regard to pre-MF.
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